ArticleCancer science2020
Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Challenging aggressive surgical strategies in extraabdominal desmoid tumors: Is tumor volume the missing key?Acta orthopaedica et traumatologica turcica · 2026Article
- Desmoid Tumors-Experience from a Referral Center, Part 1: Multidisciplinary Review and Practical Recommendations.Cancers · 2025Review
- Risk factors for postoperative recurrence of desmoid tumors: a retrospective cohort analysis.Frontiers in oncology · 2025Article
- Aggressive atypical cystic fibromatosis of the pancreas: a case report and literature review.Frontiers in oncology · 2025Article
- Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.Frontiers in oncology · 2024Article
- Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors.Clinics in colon and rectal surgery · 2023Review
- Extra‑abdominal recurrent aggressive fibromatosis: A case series and a literature review.Molecular and clinical oncology · 2023Article
- Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.Cancer medicine · 2023Article
- Misdiagnosed desmoid fibromatosis of the chest wall presenting in emergency like as recurrence of post-traumatic hematoma: A case report and review of the literature.International journal of surgery case reports · 2022Article
- Extra-abdominal desmoid fibromatosis: An evaluation of clinical factors affecting local recurrence rates.Acta orthopaedica et traumatologica turcica · 2021Article
- Less-invasive fascia-preserving surgery for abdominal wall desmoid.Scientific reports · 2021Article
- The Role of Radiation Therapy for Symptomatic Desmoid Tumors.Current treatment options in oncology · 2021Review
- Postoperative Adjuvant Radiotherapy Can Delay the Recurrence of Desmoid Tumors After R0 Resection in Certain Subgroups.Frontiers in surgery · 2021Article
- Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.Cancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 1 country.
Funding
Abstract
This study was undertaken to clarify the risk factors, including the mutation status of CTNNB1, for the local recurrence after surgery of the rare disease desmoid-type fibromatosis. It was designed as a multiinstitutional joint research project with 7 major centers in Japan participating. The committee members of 7 major medical centers specializing in bone and soft tissue tumors formed this study group to develop clinical care guidelines. Of 196 cases with specimens and medical records collected from the 7 institutions, 88 surgically treated ones were analyzed regarding clinicopathologic prognostic factors including CTNNB1 mutation status. Excluding R2 cases (n = 3), 5-year local recurrence-free survival (LRFS) was 52.9%. No case had received pre- or postoperative radiotherapy. Univariate analysis revealed that extremity location (P < .001) and larger size (8 cm or more, P = .036) were significant adverse risk factors for LRFS. Multivariate analysis indicated that extremity location (P < .001) was a significantly adverse factor in addition to recurrent tumor (P = .041), S45F mutation (P = .028), and R1 surgical margin (P = .039). Preoperative drug treatment, including nonsteroidal antiinflammatory drugs, did not reduce the incidence of local recurrence (P = .199). This is the first study to analyze the factors correlating with outcomes of surgical treatment, including CTNNB1 mutation status, in a relatively large number of cases from an Asian country. Tumor location was found to be the most influential prognostic factor for local recurrence, similar to the results from Europe and North America. The development of more sensitive method(s) for determination of CTNNB1 mutation is a priority for future study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.